

Journal of Parenteral and Enteral Nutrition

Can functional electrical stimulation-assisted cycle ergometry replace insulin infusion in critically ill patient? A nested sub-study in a randomised controlled trial with 6 months follow-up

| | |
|-------------------------------|--|
| Journal: | <i>Journal of Parenteral and Enteral Nutrition</i> |
| Manuscript ID | JPEN-2021-03-079 |
| Manuscript Type: | Brief Communication |
| Date Submitted by the Author: | 20-Mar-2021 |
| Complete List of Authors: | <p>Waldauf, Petr; Charles University, Fac Med 3, Dept. of Anaesthesia and Intensive Care Medicine; University Hospital Kralovske Vinohrady Urban, Tomas; Charles University, Fac Med 3, Dept. of Anaesthesia and Intensive Care Medicine; University Hospital Kralovske Vinohrady, Dept. of Burns</p> <p>Krajcova, Adela; Charles University, Fac Med 3, Dept. of Anaesthesia and Intensive Care Medicine</p> <p>Jiroutkova, Katerina; Charles University, Fac Med 3, Dept. of Anaesthesia and Intensive Care Medicine; University Hospital Kralovske Vinohrady</p> <p>Bakalar, Bob; Charles University, Fac Med 3, Dept. of Anaesthesia and Intensive Care Medicine; University Hospital Kralovske Vinohrady, Dept. of Burns</p> <p>Blahutova, Barbora; Charles University, Fac Med 3</p> <p>Rasova, Kamila; Charles University, Fac Med 3, Dept. of Rehabilitation; University Hospital Kralovske Vinohrady</p> <p>Lippertova-Grunerova, Marcela; Charles University, Fac Med 3, Dept. of Rehabilitation; University Hospital Kralovske Vinohrady</p> <p>Gojda, Jan; Fakultni Nemocnice Kralovske Vinohrady, Department of Internal Medicine ; Charles University, Fac Med 3, Laboratory of Clinical Physiology</p> <p>Duska, Frantisek; Charles University, Fac Med 3, Dept. of Anaesthesia and Intensive Care Medicine; University Hospital Kralovske Vinohrady, Laboratory of Bioenergetics</p> |
| Keywords: | Critical care < Research and Diseases, Drug-nutrient interactions < Nutrition, Adult < Life Cycle |
| Abstract: | <p>Background: Functional electrical stimulation-assisted cycle ergometry (FESCE) can deliver active exercise to critically patients including those who are sedated. Aerobic exercise is known to stimulate skeletal muscle glucose uptake. We asked whether FESCE can reduce intravenous insulin requirements and improve insulin sensitivity in intensive care patients.</p> <p>Method: We performed an a priori planned secondary analysis of data from an outcome-based randomised-controlled trial (NCT 02864745) of FESCE-based early mobility programme vs. standard of care in mechanically ventilated patients. We analysed glucose profile, glucose intake and insulin requirements during ICU stay in all enrolled patients.</p> |

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

| | |
|--|--|
| | <p>In a nested subgroup we performed hyperinsulinemic (120 mIU.m-2.min-1) euglycemic clamp at days 0, 7 and 180 (n=30, 23 and 11, respectively).</p> <p>Results: We randomised 150 patients 1:1 to receive intervention or standard of care. Seventeen (23%) patients in each study arm had a history of diabetes. During ICU stay patients received 137±65 and 137±88 g/day of carbohydrates (p=0.97), and 31 vs. 35 (p=0.62) of them required insulin infusion to maintain blood glucose 8.61±2.82 vs. 8.73±2.67 mM (p=0.75, n= 11254). In those treated with insulin, median daily dose was 53 (IQR 25-95) vs. 62 (IQR 26-96) IU in the intervention and control arm, respectively (p=0.44). In the subgroup of patients undergoing hyperglycaemic clamps, insulin sensitivities improved similarly and significantly from acute and protracted critical illness towards 6 months post discharge.</p> <p>Conclusion: Functional electrical stimulation-assisted cycle ergometry-based early mobility programme does not significantly reduce insulin requirements in critically ill patients on mechanical ventilation.</p> |
| | |

SCHOLARONE™
Manuscripts

1
2
3
4
5
6 Can functional electrical stimulation-assisted cycle ergometry replace insulin infusion in
7
8 critically ill patient? A nested sub-study in a randomised controlled trial with 6 months
9
10 follow-up
11
12
13
14

15 Petr Waldauf, MD^{1*}, Tomáš Urban MSc^{1*}, Adéla Krajčová, MD, PhD¹, Kateřina Jiroutková, MD, PhD¹,
16
17 Barbora Blahutová MD¹, Bob Bakalář MD¹, Kamila Řasová PhD², Marcela Grünerová-Lippertová MD,
18
19 PhD², Jan Gojda MD, PhD³ and František Duška MD, PhD¹
20
21
22
23

24 ¹Department of Anaesthesia and Intensive Care Medicine, Charles University, The Third Faculty of
25
26 Medicine and FNKV University Hospital Prague, Czech Republic
27
28

29 ²Department of Rehabilitation, Charles University, The Third Faculty of Medicine and FNKV
30
31 University Hospital Prague, Czech Republic
32

33 ³Department of Medicine, Charles University, The Third Faculty of Medicine and FNKV University
34
35 Hospital Prague, Czech Republic
36
37
38

39
40 *TU and PW contributed equally and shall be considered joint first authors
41

42 Corresponding author:
43

44 Frantisek Duska,
45

46
47 Dept. of Anaesthesia and Intensive Care Medicine
48

49 Srobarova 50
50

51
52 10034 Prague, Czech Republic
53

54 E-mail: frantisek.duska@lf3.cuni.cz
55

56
57 Phone: +420608405541
58
59
60

Abstract

Background: Functional electrical stimulation-assisted cycle ergometry (FESCE) can deliver active exercise to critically patients including those who are sedated. Aerobic exercise is known to stimulate skeletal muscle glucose uptake. We asked whether FESCE can reduce intravenous insulin requirements and improve insulin sensitivity in intensive care patients.

Method: We performed an *a priori* planned secondary analysis of data from an outcome-based randomised-controlled trial (NCT 02864745) of FESCE-based early mobility programme vs. standard of care in mechanically ventilated patients. We analysed glucose profile, glucose intake and insulin requirements during ICU stay in all enrolled patients. In a nested subgroup we performed hyperinsulinemic ($120 \text{ mIU}\cdot\text{m}^{-2}\cdot\text{min}^{-1}$) euglycemic clamp at days 0, 7 and 180 ($n=30, 23$ and 11 , respectively).

Results: We randomised 150 patients 1:1 to receive intervention or standard of care.

Seventeen (23%) patients in each study arm had a history of diabetes. During ICU stay patients received 137 ± 65 and 137 ± 88 g/day of carbohydrates ($p=0.97$), and 31 vs. 35 ($p=0.62$) of them required insulin infusion to maintain blood glucose 8.61 ± 2.82 vs. 8.73 ± 2.67 mM ($p=0.75$, $n=11254$). In those treated with insulin, median daily dose was 53 (IQR 25-95) vs. 62 (IQR 26-96) IU in the intervention and control arm, respectively ($p=0.44$). In the subgroup of patients undergoing hyperglycaemic clamps, insulin sensitivities improved similarly and significantly from acute and protracted critical illness towards 6 months post discharge.

Conclusion: Functional electrical stimulation-assisted cycle ergometry-based early mobility programme does not significantly reduce insulin requirements in critically ill patients on mechanical ventilation.

Key words: critically ill; glucose control; insulin resistance; hyperinsulinaemic clamp

1
2
3 Abbreviations: BMI = body mass index; ICU = intensive care unit; IQR = interquartile range;
4
5 FESCE = functional electrical stimulation-assisted cycle ergometry; M-value = insulin-
6
7 mediated glucose disposal; RAPA score = rapid assessment of physical activity
8
9

10
11
12
13 Conflict of interests: None declared.
14
15
16

17
18 Clinical Relevancy Statement: Treatment of hyperglycaemia of the critically ill with
19
20 continuous intravenous insulin infusion is not without risks. In this paper we show how the
21
22 delivery of early mobility programme, which includes electrical exercise, influences insulin
23
24 sensitivity and glucose control in enterally fed general ICU patients. In addition, this study is
25
26 the first one to show natural evolution of critical illness-induced insulin resistance measured
27
28 by serial hyperinsulinaemic clamps in the ICU and 6 months afterwards.
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

Insulin resistance is a well-recognized phenomenon in critically ill patients¹. Acute injury, inflammation, and catecholamine surge induce a catabolic response where glycogen, fat and proteins are degraded to provide substrates for immune cells and wound healing. Bedrest, insulin counter-acting drugs such as steroids or vasopressors, and carbohydrate delivery in the form of artificial nutrition may further exacerbate hyperglycaemia, which has repeatedly been associated with ICU morbidity and mortality, even after adjustments to disease severity². Insulin infusion is effective in controlling blood glucose levels, but it may increase risk of hypoglycaemia and mortality^{3,4}. In healthy subjects skeletal muscle is the main organ responsible for insulin-mediated glucose disposal and even a short bout of aerobic exercise increases glucose uptake up to 5-fold⁵. Animal studies suggest that mechano-signalling pathways exist in skeletal muscle and can circumvent molecular pathways affected by insulin resistance⁶. Technology advances, such as functional electrical stimulation-assisted cycle ergometry (FESCE) allow delivery of active exercise even before the patient regains consciousness^{7,8} and it is tempting to hypothesise that compared to standard of care, a FESCE-based early mobility programme delivered to mechanically ventilated patients would reduce intravenous insulin requirements and increase insulin-mediated glucose disposal during hyperinsulinaemic clamp. In this study, we also aimed to investigate the dynamics of insulin sensitivity during and 6 months after critical illness.

Materials & Methods

We performed an *a priori* planned secondary analysis of an outcome-based prospective randomised controlled trial Electric Mobility & Insulin Resistance (EMIR, NCT02864745) performed in intensive care of FNKV University Hospital in Prague. Clinical

1
2
3 outcomes are reported elsewhere [Waldauf, Thorax 2021], full protocol of the study has been
4
5 published⁷ and details can also be found in Supplementary Appendix.
6
7

8 In brief: Mechanically ventilated adult critically ill patients, who were expected to
9
10 need a protracted (>7 days) ICU stay were recruited within 72 hours of hospital admission.
11
12 Exclusion criteria include bedridden pre-morbid status and contraindications to FESCE such
13
14 as limb fractures or pacemaker. The standard care arm underwent standard rehabilitation
15
16 delivered by personnel not involved in the study. In the intervention arm, the rehabilitation
17
18 is protocolled according to patient's condition and degree of cooperation with a dedicated
19
20 full-time study physiotherapists aiming to deliver 90 min of exercise a day, 7 days a week.
21
22 Before patients re-gained the ability to engage in the mobilisation programme, they received
23
24 2 sessions of FESCE (RT-300, Respiratory Therapies, USA) per day. This technique involved
25
26 synchronised transcutaneous electrical stimulations of the gluteal, hamstrings and quadriceps
27
28 muscles on both legs to produce a coordinated pattern of movements on a supine bicycle.
29
30 The exercise intervention continued until day 28 or ICU discharge, whichever occurred earlier.
31
32 All other aspects of intensive care (including nutrition and insulin treatment) were driven by
33
34 clinical team, who were not directly involved in the study, but not blinded to patient's
35
36 treatment allocation. Nutrition was delivered preferably enterally (Supportan, Fresenius Kabi,
37
38 Germany) as tolerated with the aim to deliver 1.5 g of protein/kg/day. Insulin was started
39
40 when blood glucose level reached 11 mM and sliding scale insulin infusion rate was then
41
42 adjusted by a bedside nurse aiming blood glucose levels 6-8 mM. Arterial blood glucose levels
43
44 were checked in all patients at 05:00, 17:00 and 22:00 by blood gas analyser ABL-90
45
46 (Radiometer, Denmark) and ad hoc as needed as per bedside nurse discretion by a portable
47
48 glucometer. Patient's vital functions, all laboratory data incl. blood glucose levels and data
49
50 from syringe drivers are automatically and in real time uploaded into the clinical information
51
52
53
54
55
56
57
58
59
60

1
2
3 system (MetaVision, ver. 5, IMD-Soft, Israel). We have extracted data on blood glucose levels,
4
5 glucose intake and insulin dose from these (See Supplementary Appendix and Fig. S1 for
6
7 details).
8
9

10 *Metabolic studies.* In a subgroup of patients whose representatives specifically
11 consented to it (see Flowchart in Supplementary Fig. S1), we performed hyperglycaemic
12 euglycaemic clamps at fasting state in the morning of day 1 (baseline). These studies were
13 repeated in ICU after 7 day (n=23) and in outpatients after 180 days (range 171-186, n=11).
14
15 At baseline arterial blood sample for measurement of fasting blood glucose, insulin and C-
16 peptide was taken. After a 10-min priming infusion at a double rate, insulin infusion (1 unit/ml
17 in 0.9% saline) was held constant at $120 \text{ mIU}\cdot\text{min}^{-1}\cdot\text{m}^{-2}$ BSA for consequent 110 min. Blood
18 glucose concentration was determined every 5 min using StatStrip (Nova Biomedical,
19 Waltham, MA, USA). Blood glucose concentration was clamped at $\sim 5 \text{ mmol/L}$ by infusion of
20 variable amounts of glucose. The total body glucose disposal rate (M-value) was calculated
21 from the final 30 min (steady-state) and was used as a measure of insulin sensitivity after
22 adjustment to body weight. Insulin clamps at follow-up visit (Day 180) were performed
23 similarly, with two intravenous cannulas, one in an antecubital vein for the infusion of insulin
24 and glucose, and the other retrograde into a dorsal hand vein for sampling of arterialised
25 blood using heated hand technique.
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45

46
47 *Calculations and statistics.* Differences between groups were tested using two-sided Welch t-
48 test, Wilcoxon rank sum test, or linear mixed effect model with random intercept, where
49 appropriate, and $p < 0.05$ is considered significant. All calculations were performed in R and R
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

Results:

We enrolled 150 patients into the trial, out of which 31 consented to undergo serial insulin clamps. Baseline characteristics of enrolled subjects is given in Table 1.

| | All patients (n=150) | Subgroups | | | | P value |
|---|------------------------------|-----------------------------------|--|---|-------------------------------------|------------|
| | | Intervention group (n=75) | | Control group (n=75) | | |
| | | Consent to clamp YES (n=16) | Consent to clamp NO (n=59) | Consent to clamp YES (n=15) | Consent to clamp NO (n=60) | |
| Age (mean±SD) | 61.1±15.2 | 58±17 | 61±15 | 64±11 | 62±16 | 0.665 |
| Sex (M/F) | 110/40 | 12/4 | 41/18 | 10/5 | 47/13 | 0.663 |
| BMI | 30.1±7.4 | 29.2±5.9 | 29.4±6.5 | 33.3±8.1 | 29.9±8.1 | 0.428 |
| APACHE II (median [IQR]) | 21.8±6.4 | 22±5 | 23±5 | 27±7 | 22±7 | 0.045 |
| Days from ICU admission to recruitment | 1.2 (IQR 0.8-1.8) | 1.4±0.8 | 1.3±0.8 | 1.4±0.7 | 1.2±0.8 | 0.895 |
| History of diabetes* (%) | 34 (23%) | 6/10 (38%) | 11/48 (19%) | 7/8 (47%) | 10/50 (17%) | 0.003 |
| Pre-admission Charlson comorbidity score (median [IQR]) | 3 (IQR1-4) | 2.9±2.0 | 2.7±2.4 | 3.7±2.8 | 3.2±2.2 | 0.405 |
| RAPA Score (median [IQR]) | 1 (IQR 1-4) | 2.7±2.3 | 2.4±2.0 | 2.9±2.3 | 3.0±2.4 | 0.556 |
| Diagnostic category (trauma/surgical/medical) | 51/19/81 | 8/3/5 | 20/3/36 | 4/1/10 | 19/12/29 | 0.087 |
| Sepsis or septic shock on admission (Yes/No [%Yes]) | 37 (24.7%) | 5/11 (31%) | 14/45 (24%) | 5/10 (33%) | 13/47 (22%) | 0.742 |

Table 1: Baseline study subject characteristics.

Patients in intervention and control arms stayed for a median of 12 (IQR 7;21) and 12 (IQR 6;19) days in ICU ($p=0.76$ log-rank test) and received 137 ± 65 and 137 ± 88 g/day of carbohydrates ($p=0.97$) and 80 ± 24 vs 50 ± 10 min ($p<0.001$) of rehabilitation a day. In total, there were 5659 and 5595 blood glucose measurements in the study. There was no difference in blood glucose control between groups as average blood glucose was 8.61 ± 2.82 vs. 8.73 ± 2.67 ($p=0.75$) in the intervention vs. control groups, respectively. There were 11 (0.2%) and 16 (0.3%) blood glucose values were below 3.4 mM in intervention and control arms, respectively (Odds ratio of hypoglycaemia 0.7 [95%CI 0.3/1.6], $p=0.44$). To control blood

1
2
3 glucose, 31 (41%) and 35 (47%) patients needed insulin infusion during their ICU stay (Odds
4
5 ratio of needing insulin in intervention arm 0.81 (95%CI 0.4-1.6, p=0.62). The median daily
6
7 dose in those who received insulin was 53 (IQR 25-95) and 62 (26-96) IU of insulin in
8
9 intervention and control arms, respectively (p=0.44). Mean daily dose of insulin in all patients
10
11 adjusted to actual body weight was 0.25 ± 0.35 and 0.27 ± 0.27 IU.kg⁻¹.day⁻¹ (n=150, p=0.67),
12
13 whilst mean adjusted doses in patients receiving insulin were 0.60 ± 0.28 vs. 0.58 ± 0.34 IU.kg⁻¹.
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Insulin-mediated glucose disposal. As shown in Figure 1 insulin-mediated glucose disposal during hyperinsulinaemic clamp improved significantly in both groups throughout the course of critical illness and continued during recovery phase to reach levels measured for normal subjects⁹. In order to rule out the effect of non-survivors, we have also separately analysed only patients who survived ICU until day 7 and the improvement of insulin sensitivity remained significant (See Table S2 in the Supplementary appendix). There were no significant differences between intervention and control groups.




Figure 1: A) Mean insulin doses in all patients with 95% confidence of intervals. B) Density diagram of blood glucose levels. C) Prediction of difference in study groups of M-value corrected over different time visits. Note: M-value is expressed as glucose infusion rate space corrected, units = $\text{mg} \cdot \text{kg}^{-1} \cdot \text{min}^{-1}$. Grey zone represents published⁹ normal range in age-matched population.

Discussion

There are two main findings of this study. Firstly, early mobility programme does not significantly improve glucose control or reduce insulin requirements in critically ill patients. This is despite exercise intervention has successfully been delivered and there is a clear and

1
2
3 significant separation of rehabilitation duration between treatment groups, which mostly
4 consists of 29 min/day of FESCE. There are few possible explanations of this results, which
5 contrasts with previous studies showing that early mobilization could decrease insulin
6 requirements in ICU patients¹⁰. In healthy volunteers, unloaded FESCE increased energy
7 expenditure similarly to 25W aerobic exercise⁹, but across-leg metabolic characteristics differ
8 from volitional cycling and it is possible that it also fails to activate mechano-signalling
9 pathways⁶ that would activate glucose uptake. In addition, it seems from glucose profiles that
10 glucose control strategy was quite liberal compared to Patel's study¹⁰. This, together with the
11 fact that 23% of our cohort had pre-existing diabetes, resulted in relatively high insulin
12 requirements in those who needed insulin treatment ($\sim 0.6 \text{ IU.kg}^{-1}.\text{day}^{-1}$), whilst in Patel's
13 study¹⁰ the effect of early mobilization was only seen in low-insulin subgroup ($< 0.15 \text{ IU.kg}^{-1}.$
14 day^{-1}). In fact, we have seen a trend to a reduction of proportion of patients needing insulin
15 infusion in the intervention arm and it should be stressed that with 150 subjects and 47%
16 insulin treatment in the control group, our study was only powered to detect (at $\alpha=0.05$ and
17 $\beta=0.2$) a reduction of the need of insulin treatment below 24% (or < 18 out of 75 patients) in
18 the intervention group. Lastly, the dose of exercise in the control group (50 min/day) in our
19 study was unusually and unexpectedly high, possibly due to Hawthorne effect¹¹.

20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45 Second important and innovative finding of this study is that we, to our knowledge for
46 the very first time, assessed by serial euglycaemic hyperinsulinaemic clamps the evolution of
47 insulin sensitivity in acute and protracted critical illness, and then 6 months afterwards. We
48 have seen clear and significant increases of insulin-mediated insulin sensitivity over time that
49 were not significantly affected by treatment group allocation. After 6 months high-dose-
50 insulin-mediated glucose disposal was significantly better than during protracted critical
51 illness and reached values comparable to patients with type 2 diabetes¹² or cancer¹³, but
52
53
54
55
56
57
58
59
60

1
2
3 remained lower than in lean healthy subjects of similar age in some¹⁴, but not all⁹ studies. It
4
5 should be stressed that although most baseline characteristics of patients consenting to
6
7 insulin clamps were not different to overall study population, there seems to be a selection
8
9 bias towards patients with diabetes.
10
11

12
13 In conclusion, insulin sensitivity increases during the transition from acute to chronic
14
15 phase of critical illness and further improves after 6 months. Early mobility programme based
16
17 on functional electrical stimulation-assisted supine cycle ergometry does not significantly
18
19 influence glucose control or insulin requirements in mechanically ventilated critically ill
20
21 patients.
22
23

24
25
26
27 Acknowledgements: The authors thank Dr Jana Kukulová for monitoring the database, the
28
29 team of research nurses, namely Irena Kozáková RN, Šárka Gregorová RN, Šárka Marešová
30
31 RN, Kateřina Ťopková RN and Jana Potočková for their excellent work and assistance and all
32
33 the study participants and their families. This project was funded solely and exclusively from
34
35 Grant AZV 16-28663A of Czech Ministry of Health Grant Agency (Agentura pro zdravotnický
36
37 výzkum).
38
39
40
41
42
43

44
45 Authorship Statement. P. Waldauf and T. Urban equally contributed to the conception and
46
47 design of the research; F. Duska, J. Gojda and M. Grünerová-Lippertová contributed to the
48
49 design of the research; P. Waldauf, B. Bakalář, B. Blahutová, K. Jiroutková contributed to the
50
51 acquisition and analysis of the data; all authors contributed to the interpretation of the
52
53 data; and F. Duška drafted the manuscript. All authors critically revised the manuscript,
54
55 agree to be fully accountable for ensuring the integrity and accuracy of the work, and read
56
57 and approved the final manuscript.
58
59
60

References

1. Little RA, Henderson A, Frayn KN, Galasko CS, White RH. The disposal of intravenous glucose studied using glucose and insulin clamp techniques in sepsis and trauma in man. *Acta Anaesthesiol Belg.* 1987;38(4):275-279.
2. van Steen SC, Rijkenberg S, van der Voort PHJ, DeVries JH. The association of intravenous insulin and glucose infusion with intensive care unit and hospital mortality: a retrospective study. *Ann Intensive Care.* 2019;9(1):29.
doi:10.1186/s13613-019-0507-x
3. Finfer S, Chittock DR, Su SY-S, et al. Intensive versus conventional glucose control in critically ill patients. *N Engl J Med.* 2009;360(13):1283-1297.
doi:10.1056/NEJMoa0810625
4. Brealey D, Singer M. Hyperglycemia in critical illness: a review. *J Diabetes Sci Technol.* 2009;3(6):1250-1260. doi:10.1177/193229680900300604
5. Durham WJ, Miller SL, Yeckel CW, et al. Leg glucose and protein metabolism during an acute bout of resistance exercise in humans. *J Appl Physiol.* 2004;97(4):1379-1386.
doi:10.1152/jappphysiol.00635.2003
6. Corpeno Kalamgi R, Salah H, Gastaldello S, et al. Mechano-signalling pathways in an experimental intensive critical illness myopathy model. *J Physiol.* 2016;594(15):4371-4388. doi:10.1113/JP271973
7. Waldauf P, Gojda J, Urban T, et al. Functional electrical stimulation-assisted cycle ergometry in the critically ill: Protocol for a randomized controlled trial. *Trials.* 2019;20(1). doi:10.1186/s13063-019-3745-1
8. Gojda J, Waldauf P, Hruskova N, et al. Lactate production without hypoxia in skeletal muscle during electrical cycling: Crossover study of femoral venous-arterial

- 1
2
3 differences in healthy volunteers. *PLoS One*. 2019;14(3):e0200228.
4
5
6 doi:10.1371/journal.pone.0200228
7
- 8 9. Tam CS, Xie W, Johnson WD, Cefalu WT, Redman LM, Ravussin E. Defining insulin
9
10 resistance from hyperinsulinemic-euglycemic clamps. *Diabetes Care*.
11
12 2012;35(7):1605-1610. doi:10.2337/dc11-2339
13
14
- 15 10. Patel BK, Pohlman AS, Hall JB, Kress JP. Impact of early mobilization on glycemic
16
17 control and ICU-acquired weakness in critically ill patients who are mechanically
18
19 ventilated. *Chest*. 2014;146(3):583-589. doi:10.1378/chest.13-2046
20
21
22
- 23 11. McCarney R, Warner J, Iliffe S, van Haselen R, Griffin M, Fisher P. The Hawthorne
24
25 Effect: a randomised, controlled trial. *BMC Med Res Methodol*. 2007;7:30.
26
27
28 doi:10.1186/1471-2288-7-30
29
- 30 12. Henry RR, Aroda VR, Mudaliar S, Garvey WT, Chou HS, Jones MR. Effects of
31
32 colesevelam on glucose absorption and hepatic/peripheral insulin sensitivity in
33
34 patients with type 2 diabetes mellitus. *Diabetes Obes Metab*. 2012;14(1):40-46.
35
36
37 doi:10.1111/j.1463-1326.2011.01486.x
38
39
- 40 13. Tewari N, Awad S, Duška F, et al. Postoperative inflammation and insulin resistance in
41
42 relation to body composition, adiposity and carbohydrate treatment: A randomised
43
44 controlled study. *Clin Nutr*. Published online 2018. doi:10.1016/j.clnu.2018.01.032
45
46
- 47 14. Gudbjörnsdóttir S, Sjöstrand M, Strindberg L, Wahren J, Lönnroth P. Direct
48
49 measurements of the permeability surface area for insulin and glucose in human
50
51 skeletal muscle. *J Clin Endocrinol Metab*. 2003;88(10):4559-4564.
52
53
54 doi:10.1210/jc.2003-030434
55
56
57
58
59
60

Supplementary Appendix


To paper Waldauf et al.: Can functional electrical stimulation-assisted cycle ergometry-based early mobility programme replace insulin infusion in critically ill patient? A nested sub-study in a randomised controlled trial with 6 months follow

Table of Contents

| | |
|--|----------|
| Supplementary Methods | 2 |
| Flowchart of subjects in the study | 2 |
| Follow-Ups | 2 |
| Enrollment | 2 |
| Allocation | 2 |
| Analysis | 2 |
| Full list of Enrolment Criteria | 3 |
| Inclusion Criteria: | 3 |
| Exclusion Criteria:..... | 3 |
| Individualised Rehabilitation Protocol | 3 |
| Table S1 Protocolised rehabilitation in EMIR Trial (recommendation) | 3 |
| Table S2 Description of an average treatment days | 4 |
| Table S3 Richmond Agitation Sedation Scale (RASS)..... | 5 |
| Supplementary Results | 6 |
| Table S4: Insulin sensitivity analyses..... | 6 |
| Figure S2 Number of blood glucose samples per patient / distribution | 7 |

Supplementary Methods

Flowchart of subjects in the study



Analysis
(metabolic subgroup)

Full list of Enrolment Criteria

Inclusion Criteria:

- (1) ≥ 18 years;
- (2) mechanical ventilation, or imminent need of it at presentation;
- (3) predicted ICU length of stay ≥ 7 days;

Exclusion Criteria:

- (1) known primary systemic neuromuscular disease or spinal cord lesion at admission.
- (2) severe lower limb injury or amputation;
- (3) bedridden premorbid state (Charleston Comorbidity Score >4)
- (4) approaching imminent death or withdrawal of medical treatment within 24 h;
- (5) pregnancy;
- (6) presence of external fixator or superficial metallic implants in lower limb;
- (7) open wounds or skin abrasions at electrode application points;
- (8) presence of pacemaker, implanted defibrillator or another implanted electronic medical device;
- (9) predicted as unable to receive first rehabilitation session within 72 hours of admission or transferred from another ICU after more than 24 hours of mechanical ventilation;
- (10) Presence of other condition preventing the use of FESCE or considered unsuitable for the study by a responsible medical team;
- (11) prior participating in another functional outcome-based intervention research study.

Page Break

Individualised Rehabilitation Protocol

Table S1 Protocolised rehabilitation in EMIR Trial (recommendation)

| Stage and RASS score | Control group = goal-directed standard physiotherapy | Intervention group = FESCE in addition to the goal-directed standard physiotherapy |
|----------------------|--|--|
| 0 unstable | 2x 15 minutes | FESCE 2x45 minutes* |

| | | | |
|--|---|---|---|
| 1 2 3 4 5 6 7 8 9 10 11 12 13 | RASS -5 to -3 +/-muscle relaxants | Passive/active exercises: passive and active range of motion, application of stretch reflex to upper and lower extremities and activation of global motor response, positioning in bed Respiratory-related activity | Preparation phase: about 5 minutes of passive cycling Therapeutic phase: about 35 minutes of functional electric stimulation Relaxation phase: about 5 minutes of passive cycling |
| 14 15 16 17 18 19 20 21 22 | 1 sedated RASS -5 to -3 | 1x30 minutes Passive/active exercises: passive and active range of motion, application of stretch reflex to upper and lower extremities and activation of global motor response, positioning in bed Respiratory-related activity | FESCE 2x45 minutes* Preparation phase: about 5 minutes of passive cycling Therapeutic phase: about 35 minutes of functional electric stimulation Relaxation phase: about 5 minutes of passive cycling |
| 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 | 2 transition phase RASS -1 or 1, borderline cooperation | If cooperative: 2x10 minutes Passive/active exercises: active range of motion/lightly resisted upper and lower extremities, activation of global motor response, positioning in bed Respiratory-related activity 2x5 minutes Passive/active exercises (sit up in bed) If delirious: Individualise approach max. 30 minutes If resedated: 1x15 minutes Passive/active exercises: passive and active range of motion, application of stretch reflex to upper and lower extremities and activation of global motor response, positioning in bed Respiratory-related activity | FESCE 2x45 minutes* Preparation phase: about 5 minutes of passive cycling Therapeutic phase: functional electric stimulation (about 30 min) with active cycling (about 5 min) Relaxation phase about 5 minutes of passive cycling |
| 43 44 45 46 47 48 49 50 51 52 | 3 weak RASS 0, cooperative | 2x10 minutes Active exercises: active range of motion/lightly resisted upper and lower extremities 2x5 minutes Progressive mobility: mobility activities progressing from less difficult activity in bed, active sitting on the bed 2x60 minutes Active exercise: sit out with assistance | FESCE 2x45 minutes* Preparation phase: about 5 minutes of passive cycling Therapeutic phase about: functional electric stimulation (about 15 min) with active cycling (about 20 min) Relaxation phase: about 5 minutes of passive cycling |
| 53 54 55 56 57 58 59 60 | 4 able to stand with assistance RASS 0, cooperative | 2x10 minutes Active exercises: active range of motion, low to moderate resistance against upper and lower extremities 2x30 minutes Progressive mobility: mobility activities progressing from less difficult activity in | FESCE 2x45 minutes* Preparation phase: about 5 minutes of passive cycling Therapeutic phase: functional electric stimulation (about 5 min) with active cycling (about 30 min) |

| | | |
|--|--|--|
| | bed to more difficult out of bed activities such as up to chair and ambulation | Relaxation phase: about 5 minutes of passive cycling |
|--|--|--|

Notes: FESCE functional electrical stimulation-assisted cycle ergometry, RASS = Richmond agitation and sedation scale. Categories of interventions were defined according to Consensus on exercise reporting template in the intensive care unit (Reid et al., 2018), dose and intensity according to Perme C, Chandrashekar R., 2009.

**Conducting FES cycling for set up (e.g., electrode placement, achieve muscle contractions, start cycling) took the physiotherapists about 10 - 15 minutes and take down (e.g., removing the patient from the bike and electrode removal) about next 10 minutes in addition to FES cycling.*

Table S2 Description of an average treatment days

*an average treatment day were defined as the number of days when the participant received physical rehabilitation in ICU. Data are "median of mean", that is a mean time was calculated for each participant and then, as a data were not normally distributed, a median was calculated for each trial arm (Wright et al., 2018)
Abbreviations: ICU LOS (intensive care unit length of stay), Standard (goal-directed standard physiotherapy), FESCE (Functional electrical stimulation-assisted cycle ergometry)

Note: Real time composition of the control (goal-directed standard physiotherapy) and the intervention group (FESCE in addition to the goal-directed standard physiotherapy) was influenced according to actual patient's conditions and workload on the unit.

Table S3 Richmond Agitation Sedation Scale (RASS)

| Score | Term | Description |
|-------|-------------------|---|
| +4 | Combative | Overtly combative, violent, immediate danger to staff |
| +3 | Very agitated | Pulls or removes tube(s) or catheter(s); aggressive |
| +2 | Agitated | Frequent non-purposeful movement, fights ventilator |
| +1 | Restless | Anxious but movements not aggressive vigorous |
| 0 | Alert and calm | |
| -1 | Drowsy | Not fully alert, but has sustained awakening (eye-opening/eye contact) to voice (>10 seconds) |
| -2 | Light sedation | Briefly awakens with eye contact to voice (<10 seconds) |
| -3 | Moderate sedation | Movement or eye opening to voice (but no eye contact) |
| -4 | Deep sedation | No response to voice, but movement or eye opening to physical stimulation |
| -5 | Unarousable | No response to voice or physical stimulation |

| | | |
|--|--|--------------------------------|
| | | communicate or follow commands |
|--|--|--------------------------------|

Supplementary Results

Table S4: Insulin sensitivity analyses.

Glucose and insulin values are those measured in the end of the steady state of 120 mIU.min⁻¹.m⁻² hyperinsulinaemic clamp, i.e. at 120th min.

| | Study group | Steady state glucose [mmol/L] | M value corrected [mg.kg ⁻¹ .min ⁻¹] | Ln (M value/Insulin) [mg.L.kg ⁻¹ .min ⁻¹ U ⁻¹] | |
|-----------------------|---------------------|-------------------------------|---|--|-----------|
| All samples | | | | p | P value |
| Baseline (n=30) | Intervention (n=15) | 5.5±1.0 | 3.5±1.7 | 0.136 | 2.31±1.53 |
| | Control (n=15) | 6.4±1.5 | 2.5±2.0 | | 1.84±1.50 |
| Day 7 (n=22) | Intervention (n=10) | 5.6±0.7 | 5.3±2.2 | 0.126 | 2.67±1.05 |
| | Control (n=12) | 5.6±0.6 | 4.0±1.6 | | 3.02±1.24 |
| Day 180 (n=11) | Intervention (n=4) | 5.0±0.3 | 7.9±2.0 | 0.083 | 3.33±0.26 |
| | Control (n=7) | 6.7±1.4 | 5.7±2.1 | | 3.12±0.50 |
| Only survivors | | | | | |

| | | | | | | |
|--------------------|------------------------|---------|---------|-------|-----------|-------|
| Baseline (n=23) | Intervention (n=11) | 5.6±1.1 | 4.0±1.8 | 0.110 | 2.69±1.59 | 0.397 |
| | Control (n=12) | 6.6±1.7 | 2.6±2.2 | | 2.15±1.52 | |
| Day 7 (n=21) | Intervention (n=10) | 5.6±0.7 | 5.3±2.2 | 0.124 | 2.67±1.05 | 0.428 |
| | Control (n=11) | 5.6±0.6 | 4.0±1.6 | | 3.13±1.23 | |

Figure S2 Number of blood glucose samples per patient / distribution

